$MBIO
MUSTANG BIO, INC. Stock $mbio

$mbio Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000114420418044004 Filed on August 13, 2018

Income Statement

Concept	2018 Q2	2017 Q2	2017 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue		$50.00K
YoY Change
Gross Profit		-$50.00K
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.680M	$1.670M	$2.030M
YoY Change	0.6%	263.04%	680.77%
% of Gross Profit
Research & Development	$3.557M	$500.0K	$500.0K
YoY Change	611.4%	0.0%	0.0%
% of Gross Profit
Depreciation & Amortization	$115.0K		$0.00
YoY Change
% of Gross Profit
Operating Expenses	$5.240M	$5.665M	$3.306M
YoY Change	-7.5%	444.71%	561.2%
Operating Profit	-$5.240M	-$5.665M	-$3.306M
YoY Change	-7.5%	444.71%	302.19%
Interest Expense	$150.0K	$140.0K	$90.00K
YoY Change	7.14%	-255.56%	-212.5%
% of Operating Profit
Other Income/Expense, Net	$147.0K	$136.0K	$88.00K
YoY Change	8.09%	-246.24%	-208.64%
Pretax Income	-$5.090M	-$5.530M	-$3.220M
YoY Change	-7.96%	389.38%	257.78%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.093M	-$5.529M	-$3.218M
YoY Change	-7.89%	388.0%	256.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$187.9K	-$219.3K	-$127.7K
COMMON SHARES
Basic Shares Outstanding			24.98M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2017 Q2	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.70M	$73.80M	$75.00M
YoY Change	-36.72%
Cash & Equivalents	$12.24M	$53.79M	$75.01M
Short-Term Investments	$35.00M	$20.00M
Other Short-Term Assets	$1.000M	$0.00	$0.00
YoY Change
Inventory
Prepaid Expenses	$965.0K	$8.000K	$15.00K
Receivables
Other Receivables
Total Short-Term Assets	$48.12M	$73.80M	$75.03M
YoY Change	-34.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.536M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$521.0K
YoY Change
Total Long-Term Assets	$7.557M	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$48.12M	$73.80M	$75.03M
Total Long-Term Assets	$7.557M	$0.00	$0.00
Total Assets	$55.68M	$73.80M	$75.03M
YoY Change	-24.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.700M	$4.500M	$800.0K
YoY Change	-17.78%
Accrued Expenses	$200.0K	$100.0K	$0.00
YoY Change	100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$100.0K	$0.00
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.675M	$4.762M	$811.0K
YoY Change	-22.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$400.0K
YoY Change
Total Long-Term Liabilities	$400.0K	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.675M	$4.762M	$811.0K
Total Long-Term Liabilities	$400.0K	$0.00	$0.00
Total Liabilities	$4.070M	$4.762M	$811.0K
YoY Change	-14.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$59.78M	-$25.87M	-$20.34M
YoY Change	131.11%
Common Stock	$111.4M	$94.94M	$94.55M
YoY Change	17.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$51.61M	$69.07M	$74.21M
YoY Change
Total Liabilities & Shareholders Equity	$55.68M	$73.84M	$75.03M
YoY Change	-24.6%

Cashflow Statement

Concept	2018 Q2	2017 Q2	2017 Q1
OPERATING ACTIVITIES
Net Income	-$5.093M	-$5.529M	-$3.218M
YoY Change	-7.89%	388.0%	256.37%
Depreciation, Depletion And Amortization	$115.0K		$0.00
YoY Change
Cash From Operating Activities	-$3.350M	-$970.0K	-$2.036M
YoY Change	245.36%	34.72%	251.03%
INVESTING ACTIVITIES
Capital Expenditures	-$4.740M
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$2.010M	-$20.23M	-$380.0K
YoY Change	-109.94%
Cash From Investing Activities	-$2.740M	-$20.23M	-$375.0K
YoY Change	-86.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	80.00K	-10.00K	$49.92M
YoY Change	-900.0%	-101.39%	8507.24%
NET CHANGE
Cash From Operating Activities	-3.350M	-970.0K	-$2.036M
Cash From Investing Activities	-2.740M	-20.23M	-$375.0K
Cash From Financing Activities	80.00K	-10.00K	$49.92M
Net Change In Cash	-6.010M	-21.21M	$47.51M
YoY Change	-71.66%
FREE CASH FLOW
Cash From Operating Activities	-$3.350M	-$970.0K	-$2.036M
Capital Expenditures	-$4.740M
Free Cash Flow	$1.390M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.47in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s unaudited condensed financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Due to the uncertainty inherent in such estimates actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	35000000	USD
CY2017Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	26002000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1683000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1671000	USD
CY2018Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
CY2017Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	50000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5671000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2018Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3557000	USD
CY2017Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2494000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7849000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3200000	USD
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
	us-gaap	Net Income Loss NetIncomeLoss	-11374000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8747000	USD
CY2018Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2017Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1500000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	75000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2075000	USD
CY2018Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11744000	USD
CY2017Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	34975000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3793000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3696000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	75000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	2075000	USD
CY2018Q2	us-gaap	Share Based Compensation ShareBasedCompensation	971000	USD
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	397000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2966000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	397000	USD
	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	0	USD
	ck0001680048	Issuance Of Common Stock Founder Agreement Expenses IssuanceOfCommonStockFounderAgreementExpenses	1232000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	5240000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	5665000	USD
	us-gaap	Operating Expenses OperatingExpenses	11717000	USD
	us-gaap	Operating Expenses OperatingExpenses	8971000	USD
CY2018Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	409000	USD
CY2017Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	106000	USD
CY2018Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	965000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	278000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5240000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5665000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11667000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8971000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	59832000	USD
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
	us-gaap	Depreciation Depreciation	122000	USD
	us-gaap	Depreciation Depreciation	0	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	48118000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	61361000	USD
CY2018Q2	ck0001680048	Property Plant And Equipment Excluding Assets Under Construction PropertyPlantAndEquipmentExcludingAssetsUnderConstruction	5672000	USD
CY2017Q4	ck0001680048	Property Plant And Equipment Excluding Assets Under Construction PropertyPlantAndEquipmentExcludingAssetsUnderConstruction	140000	USD
CY2018Q2	us-gaap	Interest Income Other InterestIncomeOther	147000	USD
CY2017Q2	us-gaap	Interest Income Other InterestIncomeOther	134000	USD
	us-gaap	Interest Income Other InterestIncomeOther	293000	USD
	us-gaap	Interest Income Other InterestIncomeOther	224000	USD
	ck0001680048	Stock Issued During Period Value Issued For Founders Agreement StockIssuedDuringPeriodValueIssuedForFoundersAgreement	0	USD
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26263354	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25236255	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26263354	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25236255	shares
CY2018Q2	ck0001680048	Construction In Process Net ConstructionInProcessNet	864000	USD
CY2017Q4	ck0001680048	Construction In Process Net ConstructionInProcessNet	1241000	USD
	ck0001680048	Potentially Dilutive Securities PotentiallyDilutiveSecurities	7545650	shares
	ck0001680048	Potentially Dilutive Securities PotentiallyDilutiveSecurities	7035609	shares
CY2018Q2	us-gaap	Interest Income Related Party InterestIncomeRelatedParty	0	USD
CY2017Q2	us-gaap	Interest Income Related Party InterestIncomeRelatedParty	2000	USD
	us-gaap	Interest Income Related Party InterestIncomeRelatedParty	0	USD
	us-gaap	Interest Income Related Party InterestIncomeRelatedParty	0	USD
CY2018Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000	USD
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2966000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	957000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8000	USD
CY2017Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	834756	shares
CY2018Q2	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	0	shares
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-5093000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-5529000	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	303000	USD
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	521000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	251000	USD
CY2018Q2	us-gaap	Assets Assets	55675000	USD
CY2017Q4	us-gaap	Assets Assets	63493000	USD
	ck0001680048	Share Issued During Period Valueon Exercise Of Warrants ShareIssuedDuringPeriodValueonExerciseOfWarrants	181000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	155000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2295000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5418000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27087918	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26180351	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26731616	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24301115	shares
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	50000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	13000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-413000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-345000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	51605000	USD
CY2018Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3488000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3474000	USD
CY2018Q2	ck0001680048	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	187000	USD
CY2017Q4	ck0001680048	Payables And Accruedexpenses Related Parties Current PayablesAndAccruedexpensesRelatedPartiesCurrent	137000	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	146000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8921000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3010000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3675000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3611000	USD
CY2018Q2	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	395000	USD
CY2017Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	50000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	4070000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	3661000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	35000000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	20038000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	26002000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	0	USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	75000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	575000	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	3000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2018Q2	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0	USD
CY2017Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	9558000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	111384000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	98679000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	320000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50234000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59782000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48408000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6536000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27499000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12244000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53790000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1381000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	181000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	181000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49914000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55675000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63493000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23231000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	26291000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35475000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	413000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	818000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Stock Issued1 StockIssued1	9558000	USD
	us-gaap	Stock Issued1 StockIssued1	4396000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3000000	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	MUSTANG BIO, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001680048
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	147000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	136000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	293000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14491000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20613000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5000000	shares
	ck0001680048	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	0	USD
	ck0001680048	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	1682000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6661000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1383000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	125000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	0	USD
CY2018Q2	us-gaap	Depreciation Depreciation	115000	USD

Files In Submission

Name	View Source	Status
0001144204-18-044004-index-headers.html	Edgar Link	pending
0001144204-18-044004-index.html	Edgar Link	pending
0001144204-18-044004.txt	Edgar Link	pending
0001144204-18-044004-xbrl.zip	Edgar Link	pending
ck0001680048-20180630.xml	Edgar Link	completed
ck0001680048-20180630.xsd	Edgar Link	pending
ck0001680048-20180630_cal.xml	Edgar Link	unprocessable
ck0001680048-20180630_def.xml	Edgar Link	unprocessable
ck0001680048-20180630_lab.xml	Edgar Link	unprocessable
ck0001680048-20180630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv500038_10q.htm	Edgar Link	pending
tv500038_ex3-1.htm	Edgar Link	pending
tv500038_ex31-1.htm	Edgar Link	pending
tv500038_ex31-2.htm	Edgar Link	pending
tv500038_ex32-1.htm	Edgar Link	pending
tv500038_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MBIO
MUSTANG BIO, INC. Stock $mbio

2018 Q2 Form 10-Q Financial Statement

#000114420418044004 Filed on August 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO MUSTANG BIO, INC. Stock $mbio

2018 Q2 Form 10-Q Financial Statement

#000114420418044004 Filed on August 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MBIO
MUSTANG BIO, INC. Stock $mbio